Compare NXN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXN | CALC |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6M | 91.5M |
| IPO Year | N/A | N/A |
| Metric | NXN | CALC |
|---|---|---|
| Price | $12.13 | $6.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 9.7K | ★ 149.0K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.64 | $1.42 |
| 52 Week High | $12.45 | $6.40 |
| Indicator | NXN | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 53.23 | 77.74 |
| Support Level | $11.90 | $4.64 |
| Resistance Level | $12.18 | $6.40 |
| Average True Range (ATR) | 0.10 | 0.51 |
| MACD | -0.00 | 0.14 |
| Stochastic Oscillator | 82.14 | 96.98 |
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.